文献速递腹部MR

肝细胞腺瘤在钆塞酸二钠与其他钆基对比剂增强MRI上的强化模式:个体内比较

Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison.
PubMed 文献 · Eur J Radiol · 2019-08-06

回顾性单中心研究纳入17例女性、35个病理证实的肝细胞腺瘤(83%为炎症亚型),个体内比较钆塞酸二钠与其他钆基对比剂增强MRI的强化模式。动脉期和门静脉期强化无显著差异,但钆塞酸二钠注射后2分钟及4-5分钟图像上病灶低信号更常见(2分钟:13/35 vs 1/35,P<0.001),假包膜也更常显示(13/35 vs 1/35,P=0.002)。

要点

  • 肝细胞腺瘤在钆塞酸二钠增强MRI的2分钟及4-5分钟图像上更常呈低信号,与动脉期和门静脉期强化无关。
  • 钆塞酸二钠增强后假包膜显示率更高(13/35 vs 1/35,P=0.002),阅片时需注意此征象。
  • 钆塞酸二钠与其他钆基对比剂在动脉期(P=0.625)和门静脉期(P=0.125)的强化无显著差异。

核心结论

  • 肝细胞腺瘤在钆塞酸二钠与其他钆基对比剂增强MRI上的强化模式存在显著差异,钆塞酸二钠注射后2分钟和4-5分钟图像上病灶低信号更常见,假包膜也更常显示。

研究设计与样本

  • 回顾性、经机构审查委员会批准的单中心研究,检索2008年至2017年病历,纳入17例(均为女性)至少有一个病理证实的肝细胞腺瘤、且在1年内接受过钆塞酸二钠和其他钆基对比剂肝脏MRI的患者,由两名腹部放射科医生主观评估强化模式,使用McNemar检验,P<0.05为有统计学意义。

关键影像表现/征象

  • 肝细胞腺瘤在钆塞酸二钠注射后2分钟图像上低信号更常见(13/35 vs 1/35,P<0.001),4-5分钟图像上低信号也更常见(P<0.001);假包膜在钆塞酸二钠给药后更常被观察到(13/35 vs 1/35,P=0.002)。

诊断标准与关键数值

  • 病灶强化与周围肝实质比较分为高信号、等信号或低信号;记录有无周边假包膜;动脉期强化(P=0.625)和门静脉期强化(P=0.125)在两种对比剂间无显著差异;病灶大小无显著差异(P=0.708)。

临床应用与阅片要点

  • 阅片时注意肝细胞腺瘤在钆塞酸二钠增强2分钟及4-5分钟图像上可呈低信号,且假包膜更常显示,需与其他肝脏病变鉴别。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To conduct an intraindividual comparison of the enhancement pattern of hepatocellular adenoma (HCA) on dynamic MRI study obtained following the injection of Gadoxetic acid (Gd-EOB-DTPA) and other gadolinium-based contrast agents (GBCAs).

METHOD: This is a retrospective, Institutional Review Board-approved study conducted in a single institution. A search of medical records between 2008 and 2017 revealed 17 patients (all females) with at least one pathologically-proven HCA who underwent liver MRI with Gd-EOB-DTPA and another GBCA within 1 year. Enhancement of each lesion on hepatic arterial (HAP), portal venous (PVP), 2 min and 4-5 minutes phases was subjectively evaluated by two abdominal radiologists. Lesions were categorized as hyper-, iso- or hypointense compared to the surrounding liver parenchyma. The presence of a peripheral pseudocapsule was also recorded. The differences in lesion enhancement were assessed using the McNemar Test. A p-value <0.05 was considered statistically significant.

RESULTS: The final population included 35 HCAs (83% inflammatory subtype). There was no significant difference in lesion size (P = 0.708) and enhancement on HAP (P = 0.625) or PVP (P = 0.125). HCAs showed more frequently hypointensity on 2 min (13/35 vs. 1/35, P < 0.001) and 4-5 minutes (P < 0.001) images obtained after injection of Gd-EOB-DTPA compared to those obtained after other GBCAs. A pseudocapsule was more frequently noted after administration of Gd-EOB-DTPA (13/35 vs 1/35, P = 0.002).

CONCLUSIONS: Enhancement pattern of HCA differs significantly after the injection of Gd-EOB-DTPA compared to other GBCAs. Lesion hypointensity on 2 min and 4-5 minutes images is more frequent when using Gd-EOB-DTPA.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Cannella R, Brancatelli G, Rangaswamy B, et al. Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison. Eur J Radiol. 2019. PMID: 31437747. doi:10.1016/j.ejrad.2019.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。